
    
      In this phase 3 double blind placebo controlled, efficacy study, women who have had a
      urogenital chlamydia or gonorrhea infection at any time over the 16 weeks preceding the
      enrollment Visit with one or more risk factors, or found to be positive for either infection
      at Screening Visit with one or more risk factors will be enrolled. After a screening period
      of up to 35 days, women will be randomized to receive either EVO100 vaginal gel or placebo.
      Each woman will participate in the study until she has completed 16 weeks of study medication
      or observation or tests positive for CT or GC infection.
    
  